Mankind Pharma to Acquire Stake in Armed Cell
Mankind Pharma is purchasing a 70 percent stake in Armed Cell Therapeutics for €48 million to expand its cancer research portfolio.
Updated on Oct. 15, 2026 in Healthcare
Live Poll
Do you support domestic pharmaceutical companies acquiring foreign biotech firms to expand their global reach?
Mankind Pharma announced plans to acquire a 70 percent stake in Armed Cell Therapeutics for €48 million. The transaction will be facilitated through a Netherlands subsidiary of the firm.
Why it matters
This investment serves as a strategic entry into next-generation CAR-T cancer therapies, supporting the company's objective to build a global innovation-led pharmaceutical business.
Mankind Pharma is acquiring a 70% stake in Armed Cell Therapeutics for €48 million. Exports accounted for 15% of Mankind Pharma consolidated revenue in the quarter ending December 2025.
The players
Mankind Pharma
This pharmaceutical company is an India-based firm that has recently pursued aggressive expansion through the acquisition of oncology and transplant assets.
Armed Cell Therapeutics
Based in Belgium, this biotech firm specializes in the development of CAR-T cell cancer therapies for complex conditions like lymphoma and lung cancer.
Paul Stoffels
He is one of the founders of Armed Cell Therapeutics.
John Mellors
He is one of the founders of Armed Cell Therapeutics.
The details
The acquisition provides Mankind Pharma with access to a cell-therapy research platform and a clinical pipeline targeting non-Hodgkin lymphoma and small-cell lung cancer. These research programs currently span facilities in both Europe and the United States.
Timeline
2022: Mankind Pharma acquired Panacea Biotec Pharma oncology and transplant brands.
2024: Mankind Pharma acquired Bharat Serums and Vaccines.
December 2025: Exports accounted for 15 percent of Mankind Pharma consolidated revenue.
October 15, 2026: Mankind Pharma announced the acquisition plan for Armed Cell Therapeutics.
Market Landscape
This deal marks a continuation of the rapid inorganic growth strategy demonstrated by the 2024 acquisition of Bharat Serums and Vaccines. It positions the company to compete more effectively in the specialized global oncology market.
The acquisition of this research platform does not immediately change current patient treatment options, as the therapies require clinical validation before becoming commercially available. Investors and stakeholders should note that the pipeline is focused on future breakthroughs in non-Hodgkin lymphoma and lung cancer care.
The takeaway
The move underscores the high-stakes investment trend in cell-therapy research as pharmaceutical firms race to secure next-generation cancer treatments. Long-term progress in this space will depend heavily on whether current research programs successfully navigate the clinical validation process.
Further reading
Learn more about the evolving sector in the Healthcare section.
Source note: This article includes information reported by Business Standard.
Live Poll
Do you support domestic pharmaceutical companies acquiring foreign biotech firms to expand their global reach?
